Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2024-10-03 Regulatory Filings
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
Regulatory Filings Classification · 1% confidence The document is a press release dated October 3, 2024, announcing the 'Positive Interim Efficacy and Safety Analysis' results for the drug Obefazimod in Ulcerative Colitis patients. It details clinical study outcomes (remission rates, safety profile) and includes quotes from medical experts and company management. This content structure—announcing key results from clinical trials, often ahead of a full scientific publication or regulatory filing—is characteristic of an Earnings Release (ER) or a general news announcement regarding operational/study progress. Since it focuses purely on study results and not comprehensive financial performance for a period (like a 10-K or IR), and it is a formal news release ('EQS-News'), it best fits the 'Earnings Release' category, which often includes operational highlights like clinical trial updates in the biotech sector, or the general 'Regulatory Filings' (RNS) as a fallback. Given the focus on study results and the format of a news announcement, ER is the most specific fit among the options for reporting key operational/clinical milestones, even if it's not strictly quarterly financial earnings. However, since it is a specific announcement of study results rather than a summary of financial performance, and it is disseminated via EQS News, it functions as a key operational update. If we strictly follow the definitions, 'ER' is for periodical financial results. Since this is a clinical trial update, and it's not a presentation (IP) or a formal report (AR/IR), the most appropriate general category for a non-financial, non-meeting-related regulatory news item is 'RNS' (Regulatory Filings/General Announcement). Given the context of biotech news releases, these clinical updates are often categorized as ERs or RNS. I will lean towards RNS as it is a general regulatory news dissemination that doesn't fit the specific financial report types.
2024-10-03 English
Abivax annonce la présentation de trois abstracts sur Obefazimod dans la rectocolite hémorragique lors du congrès UEG Week 2024
Investor Presentation Classification · 1% confidence The document is a press release from Abivax announcing that three scientific abstracts about their drug candidate, obefazimod, will be presented at the UEG Week 2024 congress. It details the content of the presentations (efficacy, safety data, oral presentation, poster presentations) and provides context about the drug and the company. This type of announcement, which publicizes upcoming scientific presentations or data releases, is best classified as an Investor Presentation (IP) if it were the presentation itself, or an Earnings Release (ER) if it contained financial results. Since it is an announcement about scientific data being presented at a conference, and it is not a formal regulatory filing like a 10-K or a general regulatory notice (RNS), it aligns most closely with providing specific information intended for investors and the scientific community regarding ongoing clinical development. However, given the options, this is a specific corporate update about clinical trial data presentation, which often falls under Investor Presentation (IP) content, or sometimes a general Regulatory Filing (RNS) if it were less specific. Since it is a detailed announcement about specific data being shared at a medical conference, it functions as an update to investors about R&D progress, making 'Investor Presentation' (IP) a strong candidate, although it is an announcement *about* presentations, not the presentation itself. Given the nature of the content (clinical trial updates and scientific presentation schedule), it is a key piece of investor information. If it were purely a notice that a report was published, RPA would apply. Since it contains substantive details about the data to be presented, IP is the most fitting category for this type of clinical/R&D update communication, even though it's a press release format. Revisiting the definitions: It is not an ER (no financial results), not an AR (not an audit report), and not an RPA (it contains substantive details, not just a notice of publication). It is a detailed update on clinical progress shared via a press release, which is often categorized as an Investor Presentation (IP) when the focus is on clinical/pipeline progress. Confidence is high because the content is clearly about clinical trial data being presented at a major medical meeting.
2024-09-26 French
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
Regulatory Filings Classification · 1% confidence The document is a press release dated September 26, 2024, announcing that Abivax will present scientific abstracts regarding its drug candidate, obefazimod, at the UEG Week 2024 conference. It details the presentation titles, presenters, and dates. This type of announcement, which informs the public about upcoming scientific presentations or data disclosures, is typically classified as an Investor Presentation (IP) if it were the presentation itself, or an Earnings Release (ER) if it contained financial results. Since this document is purely an announcement about future scientific data presentation at a conference, and not a comprehensive financial report (like 10-K or IR) or a formal regulatory filing, it best fits the category of providing information to investors about ongoing clinical/research activities. However, given the options, it is a specific announcement about clinical data being shared at a medical conference. It is not a formal Earnings Release (ER) as it contains no financial results, nor is it a proxy statement (DEF 14A) or a general regulatory filing (RNS). It is an announcement detailing upcoming scientific data dissemination, which often accompanies or precedes an Investor Presentation (IP). Since the content is focused on clinical trial data presentation, 'Investor Presentation' (IP) is the most fitting category for this type of corporate communication, even though it is an announcement *about* presentations rather than the presentation slides themselves. If 'RPA' (Report Publication Announcement) were used for any announcement, it would fit, but 'IP' captures the subject matter better than the general 'RNS' fallback.
2024-09-26 English
Abivax fait le point sur la stratégie du programme de traitement combiné dans la RCH et annonce les données précliniques précoces de combinaison d’obefazimod et d’étrasimod dans un modèle murin MICI
Regulatory Filings Classification · 1% confidence The document is a press release dated September 25, 2024, announcing preclinical data updates regarding a combination therapy (obefazimod and etrazimod) for Ulcerative Colitis (UC) and Crohn's disease. It includes quotes from management (CEO, CMO) and an external expert, details on the preclinical study methodology, and forward-looking statements. This format—a formal announcement of scientific/business progress, often released outside of mandatory quarterly filings—is characteristic of an Earnings Release (ER) or a general press release detailing operational updates. Since it focuses on scientific/pipeline progress rather than summarizing overall financial performance (which would be an ER or IR), and it is not a transcript (CT), a formal report (10-K/IR), or a proxy statement (DEF 14A/PSI), it fits best as an Earnings Release (ER) if it's part of a regular reporting cycle, or a general Regulatory Filing (RNS) if it's purely scientific/pipeline news. Given the structure and the inclusion of management commentary on strategy and future data releases, it strongly resembles an Earnings Release (ER) which often contains operational highlights alongside financial context (though financials are minimal here, the structure is typical of an ER press release). However, since it is primarily a scientific update and not explicitly labeled as a quarterly financial summary, the most appropriate general category for a significant, non-standard operational/scientific update that is not a full report is often RNS, but ER is used for periodic results announcements. Since it mentions upcoming data releases and strategic updates, and is a formal press release, ER is a strong candidate. If we strictly follow the definitions, it's not a full 'Interim Report' (IR) or 'Annual Report' (10-K). It is an announcement of progress. Given the context of biotech press releases, this type of announcement often accompanies or substitutes for a formal ER. I will classify it as an Earnings Release (ER) as it serves to update the market on recent progress, which is a key function of ERs, even if the focus is scientific. If it were purely a scientific abstract release, RNS would be better, but the management commentary pushes it towards ER.
2024-09-25 French
Abivax Provides Update on Ulcerative Colitis Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease Mouse Model
Regulatory Filings Classification · 1% confidence The document is a press release dated September 25, 2024, issued via EQS News. It announces an update on a combination therapy program strategy and presents early preclinical data for Obefazimod and Etrasimod in an IBD mouse model. It contains forward-looking statements, quotes from management, and contact information typical of a corporate news release regarding R&D progress. This type of announcement, which provides key operational and scientific updates but is not a full financial report (like 10-K or IR) or a formal regulatory filing for a specific event (like AGM or DIV), fits best under the general category for corporate news or regulatory announcements that don't fit elsewhere. Since it is an announcement of scientific progress and strategy updates, and not a formal financial report, 'Regulatory Filings' (RNS) serves as the most appropriate general category for non-standard corporate news releases, although 'Investor Presentation' (IP) or 'Earnings Release' (ER) might be considered if it were summarizing periodic results. Given the focus on preclinical data and strategy update, RNS is the best fit as a general corporate disclosure.
2024-09-25 English
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.08.24.
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a formal announcement dated September 19, 2024, detailing the 'Nombre d'actions composant le capital social et nombre total de droits de vote' (Number of shares comprising the share capital and total number of voting rights). It explicitly references compliance with French commercial code (Article L. 233-8 II) and AMF regulations (Article 223-16), providing a table with the share count and voting rights as of August 31, 2024. This type of mandatory periodic disclosure regarding share capital structure and voting power thresholds is a specific regulatory filing related to ownership and capital structure, but it does not fit perfectly into the standard US SEC forms (like 10-K, ER, etc.). Among the provided definitions, it most closely relates to changes in share structure or major ownership notifications. Since it is a mandatory disclosure about the total number of shares and voting rights, it is a notification about the capital structure. The closest fit among the provided codes that deals with capital structure changes or significant ownership notifications is 'SHA' (Share Issue/Capital Change) or 'MRQ' (Major Shareholding Notification). Given that this is a routine, periodic update on the total capital base and voting rights, it is a fundamental capital structure disclosure. 'SHA' covers 'new share issues, stock splits, or other capital changes.' This disclosure confirms the current capital base, which is a direct consequence of capital changes. It is not a general regulatory filing (RNS) because it is highly specific. It is not a Director's Dealing (DIRS) or Major Shareholding Notification (MRQ) as it reports the total outstanding shares, not an individual's transaction crossing a threshold. Therefore, 'SHA' is the most appropriate classification for a formal statement of the total share capital and voting rights.
2024-09-19 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.